PGHH Announces Key Management Changes: New CFO Appointed, Director Transitions
PGHH Board approved leadership changes effective July 1, 2026. Ms. Srividya Srinivasan appointed Executive Director & CFO. Mr. Ghanashyam Hegde re-designated Non-Executive Director. Mr. Gaurav Bhartia resigns as CFO. All changes effective July 1, 2026, except for Hegde's cessation as CS/Compliance Officer on June 30, 2026.
Changes in key managerial personnel, particularly the Chief Financial Officer and Directors, can have a medium-term impact on the company's strategic direction, financial management, and operational execution. The appointment of a new CFO with extensive experience is a notable event.
The announcement details routine management and directorial changes within the company, including resignations and appointments. While these are significant internal events, they do not inherently indicate a positive or negative shift in the company's performance or outlook based solely on the information provided.
Procter & Gamble Hygiene and Health Care Limited (PGHH) announced significant changes in its leadership team, approved at a Board meeting held on May 28, 2026.
Mr. Ghanashyam Hegde will cease to be Company Secretary and Compliance Officer effective June 30, 2026, as he moves to a regional role within P&G. He will be re-designated as a Non-Executive Director of the Company, effective July 1, 2026. Mr. Hegde is taking up the role of Vice President & Associate General Counsel – Market Operations, India, Middle East, Turkey & Africa.
Mr. Gaurav Bhartia will also step down as Chief Financial Officer on June 30, 2026, to take up a new assignment within P&G.
Ms. Srividya Srinivasan has been appointed as the new Executive Director and Chief Financial Officer, effective July 1, 2026. She holds a Bachelor of Computer Science Engineering from Anna University and an MBA in Finance from the University of Virginia, Darden School of Business. Ms. Srinivasan has been with P&G since 2005 and brings 20 years of diverse finance experience across various roles and markets, including USA, Latin America, and the Philippines. The appointment is for a period of five years, subject to Board approval at the upcoming 62nd Annual General Meeting. PGHH confirms that Ms. Srinivasan is not debarred from holding a directorial office and is not related to any of the current Directors.
What to do with a filing like this
Procter & Gamble Hygiene and Health Care Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Hygiene and Health Care Limited. Read the original for the full detail.